QT Interval Safety with Antiemetic Medications

Comparative Safety Profile

• Metoclopramide does not appear in any of the guidelines' lists of QT-prolonging medications, unlike ondansetron which is specifically mentioned as causing QT prolongation, according to the American College of Cardiology and American Heart Association guidelines 1, 2
• The American College of Cardiology recommends assessing baseline QT risk, considering medication risks, and choosing the safer option for patients with pre-existing QT prolongation, with metoclopramide 5mg being the safer choice for this patient with pre-existing QT prolongation 1, 2

Clinical Decision Algorithm

• The American College of Cardiology suggests that a patient's baseline QTc of 0.476 seconds (476 ms) is borderline prolonged, and QT of 0.504 seconds is concerning, especially when combined with the corrected QTc, with a recommendation to assess baseline QT risk 2

Additional Considerations

• The American College of Cardiology recommends avoiding combining multiple QT-prolonging medications in patients with baseline QT prolongation, and considering alternatives such as lorazepam, which may be a safe alternative antiemetic in patients with prolonged QT interval 3, 4
• The American Heart Association suggests that electrolyte abnormalities, especially hypokalemia and hypomagnesemia, can further increase the risk of QT prolongation with ondansetron, and recommends checking and correcting electrolytes 4

QTc Threshold for Holding Ondansetron (Zofran)

Evidence-Based QTc Thresholds

• The American College of Cardiology, American Heart Association, and Heart Rhythm Society guidelines establish that when QTc exceeds 500 milliseconds or when QTc increases by more than 60 milliseconds from baseline, the dose of ondansetron must be reduced or the drug discontinued 5, 6
• The American College of Cardiology, American Heart Association, and Heart Rhythm Society guidelines recommend that the dose of ondansetron must be reduced or the drug discontinued when QTc is greater than 500 ms 5, 6
• The American College of Cardiology, American Heart Association, and Heart Rhythm Society guidelines recommend that the dose of ondansetron must be reduced or the drug discontinued when QTc increase is greater than 60 ms from baseline 5, 6

Clinical Context and Risk Stratification

• High-risk patients, including those with baseline QTc greater than 450 ms (men) or 470 ms (women), require particular caution when given ondansetron 5

Critical Pitfalls to Avoid

• The American College of Cardiology recommends avoiding the combination of ondansetron with Class III antiarrhythmics (amiodarone, dofetilide, sotalol, procainamide) and other QT-prolonging medications without expert consultation 6, 7, 8, 9